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One of the most notable advances in peritoneal dial- peritoneal permeability and consequent greater difficulty
ysis (PD) technology during the past two decades has in peritoneal fluid removal. Thus, there seems to be a
been the development and introduction in clinical prac- vicious circle in long-term PD treatment, in which the
tice of a new generation of PD solutions designed to loss of renal function and development of hyper-perme-
address specific clinical and biologic aspects of the ther- able membrane require the use of more hypertonic solu-
apy. These solutions have been developed to tackle the tions, which in turn may exacerbate membrane hyperper-
issues of enhanced ultrafiltration (alternative osmotic meability and can perpetuate a state of over-hydration
agents), nutritional support (amino acid containing solu- and loss of ultrafiltration. The use of an alternative high
tions), and peritoneal membrane preservation (alternate molecular weight osmotic agent for the long dwell can
buffer systems and physiologic pH) [1–3]. Icodextrin- be an interesting alternative in preventing this situation,
based solutions have been the longest in clinical use and therefore may have a positive impact on reducing
since their development two decades ago [4], and have the unacceptably high cardiovascular mortality of PD
accumulated large clinical experience regarding their ef- patients. This is the most important systemic effect of the
ficacy and safety. This is reflected in their widespread icodextrin-based solutions. As discussed in this review,
acceptance and common use in countries where they various other positive systemic and local effects may
are available. Icodextrin-based solutions differ from the contribute to make this solution the standard prescrip-
conventional PD fluids not only in the nature of the tion for the long dwell in PD patients in the future.
osmotic agent, but also in the mechanism by which they
lead to ultrafiltration. These solutions induce effective
THE PROBLEM OF FLUID OVERLOAD INtranscapillary ultrafiltration through colloid osmosis dur-
PERITONEAL DIALYSISing dwells of more than 12 hours. Therefore, icodextrin-
based solutions promote an equal or better and more It is now widely accepted that in order to achieve good
long-lasting ultrafiltration profile than glucose solutions clinical outcomes with dialysis treatment, one should
during the long dwell without the problems of hyperos- provide adequate solute and fluid removal. Strategies to
molality and high glucose content of the latter. enhance fluid removal in dialysis patients are summa-
In parallel with the advances in PD solutions, there rized in Table 1. Solute removal has been addressed in
is growing evidence of the common presence of over- a large number of clinical studies, most recently in the
hydration in dialysis patients, particularly in anuric long- ADEMEX study [7]. However, until recently fluid re-
term PD patients, in addition to the cumulative apprecia- moval has been largely neglected in most of the studies
tion of the risk for cardiovascular mortality that chronic and guidelines published [6]. However, it is clear that
fluid overload represents [5]. The progressive loss of fluid status has gained increased interest in the PD scien-
residual renal function leads to greater reliance on peri- tific community in recent years [8]. In parallel, despite
toneal ultrafiltration for the maintenance of fluid balance the advantageous effect of PD on hemodynamic stability
[6]. If this is not pursued zealously, a state of chronic [9], cardiovascular disease remains the most common
over-hydration develops with the predictable nefarious cause of morbidity and mortality in this population
consequences. When enhanced peritoneal ultrafiltration [10, 11]. Volume overload leads to the development of
is attempted with traditional hypertonic glucose-based hypertension and left ventricular hypertrophy, which are
solutions, the greater glucose exposure may lead to higher directly associated with increased risk of sudden death,
stroke, and congestive heart failure [12]. Indeed, clinical
features of over-hydration are observed in roughly oneKey words: dialysate solution, ultrafiltration, nutritional support, mem-
brane preservation, renal replacement therapy, CAPD, APD. fourth of the patients on continuous ambulatory perito-
neal dialysis (CAPD) [13]. In a recent study, the extracel- 2002 by the International Society of Nephrology
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Table 1. Strategies to enhance fluid removal in dialysis patients they start dialysis [12]. The prevalence decreases to 40%
in CAPD patients at the end of 1 year on dialysis [17].1. Reduce salt (and fluid) intake
2. Preserve GFR and use diuretics However, after the first years on dialysis, blood pressure
3. Prescribe longer HD sessions control becomes more difficult, requiring a greater num-
4. Consider daily HD
ber of antihypertensive medications [18]. Lameire et al5. Short HD is effective but may be associated with problems related
to cardiovascular instability and sodium balance also found that although the prevalence of left ventricu-
6. Continuous dialysis (that is, PD) is advantageous as it allows contin- lar hypertrophy (LVH) and hypertension decreased sig-
uous fluid removal
nificantly in the first three years, both these risk factorsa. Glucose-based solutions are efficient for short dwells, but are
less effective in long dwells, particularly in high PSTR patients, go back to similar levels after five years, as at the start
and during peritonitis of CAPD treatment [11, 17, 19].
b. Icodextrin-based solution provides sustained ultrafiltration dur-
The results of the recently published ADEMEX studying long dwells, especially in high PSTR patients, and during peri-
tonitis [7] as well as some previous reports [20, 21] suggest that
Abbreviations are: GFR, glomerular filtration rate; HD, hemodialysis; PD, parameters other than small solute removal (Kt/V urea
peritoneal dialysis; PSTR, peritoneal small solutes transport rate. or creatinine clearance) are more important in determin-
ing clinical outcome in PD patients. The results of the
ground-breaking ADEMEX study question some of the
concepts defined by previous studies and current guide-lular volume in CAPD patients was similar to that of
lines. As an example, the CANUSA study consideredhemodialysis patients before the dialysis session, indicat-
renal and peritoneal clearances equivalent in influencinging that the CAPD patients were fluid overloaded de-
survival, and interpreted their findings of a correlationspite their seemingly stable clinical status [abstract; Wu
between total projected clearance and survival as proofet al, Perit Dial Int 21(Suppl):S8, 2002]. Similarly, Koon-
of a significant impact of small molecule clearances onings et al showed that PD patients were over-hydrated
clinical outcome [22]. However, a more detailed exami-when compared to transplanted patients (abstract; Koon-
nation of the data showed that there was no effect ofings et al, Perit Dial Int 22:142, 2002).
peritoneal clearance on outcome [23].This state of over-hydration may not be only a sign of
One important reason why residual renal clearanceclinical neglect, but may be influenced by developments
(rather than peritoneal clearance) is a predictor of pa-
during the course of PD treatment. First, during long-
tients’ clinical outcome is that the contributions of fluid
term PD treatment, the peritoneal membrane undergoes removal in peritoneal clearance and renal clearance are
functional as well as structural alterations that may be different. A higher renal Kt/V, in general, represents
the consequence of many factors such as peritonitis and increased fluid removal. On the other hand, higher peri-
continuous exposure to dialysis solutions with high con- toneal Kt/V does not necessarily mean increased fluid
centrations of glucose and glucose degradation products, removal [15]. Peritoneal fluid removal, or in other terms,
low pH, and high osmolality. The most common func- net ultrafiltration, may be negative, particularly during
tional alteration during long-term CAPD is increased the long dwell cycle and with the use of a low glucose
peritoneal small solutes transport rate (PSTR) [14], re- concentration solution [24]. By increasing the dialysis
sulting in impaired ultrafiltration and decreased dialysis dose, one can achieve higher small solute clearances even
efficiency [15]. Fluid volume control becomes more de- without net fluid removal during PD [15]. Therefore,
manding when anuria develops following the natural higher small solute clearances achieved by increasing the
progression of the underlying renal disease. Depending dialysis dose may not necessarily be associated with bet-
on the level of renal function at initiation of dialysis, ter clinical outcome, unless adequate net fluid removal
anuria will become evident in most patients within three is achieved. It is thus not surprising that the residual renal
years after the initiation of PD. In parallel, peritoneal function and peritoneal dialysis transport characteristics
ultrafiltration may decline in a subset of patients, primar- may have different effects on patients’ outcome [20, 25,
ily because of high PSTR, and clinical manifestations of 26]. By the same rationale, although incremental perito-
impaired ultrafiltration appear in as many as 30% of neal clearance in general is not considered a strong deter-
CAPD patients after six years on PD [16]. It is conceiv- minant of clinical outcome, the peritoneal transport sta-
able that taken together these two factors, the increased tus has in some studies of CAPD patients been found
PSTR with loss of ultrafiltration and declining residual to affect outcome: increased PSTR was associated with
renal function (RRF), lead to a state of chronic fluid increased mortality and decreased technique survival,
overload in PD patients, unless adequate treatment is although it is easier to achieve creatinine clearance (CCr)
initiated. RRF has a significant role in the maintenance targets for high PSTR patients [15, 27, 28]. These associa-
of adequate volume control in PD patients. It has been tions may reflect the difficulties inherent in fluid removal
reported that approximately 80% of the patients with in these patients with CAPD and traditional glucose-
based solutions. More recent studies with APD and ico-end-stage renal disease (ESRD) are hypertensive when
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dextrin use (and expected better fluid control) have not ity: fluid films within peritoneal capillaries, the capillary
endothelium, the capillary basement membrane, the inter-found this association, suggesting that volume removal
rather than the peritoneal transport function is the de- stitium, the mesothelium, and stagnant fluid films within
the peritoneal cavity (Fig. 1) [33]. The capillary endothe-termining factor (Brown et al, unpublished observation).
These findings suggest that the fluid overload caused lium constitutes a very selective barrier for solute diffu-
sion and is probably the most important resistance duringby insufficient ultrafiltration may contribute to the in-
creased mortality in anuric PD patients. It is therefore PD [33, 34]. The transport of fluid and solutes across the
capillary endothelium is generally considered to occurpossible that improved fluid balance in these patients,
especially in high transporters, will improve their clinical through a system of three pores [24]: the large pores (radii
that exceed 150 A˚) that allows the transport of macro-outcome. Undoubtedly, this will be an important area
molecules such as serum proteins, corresponding to lessfor studies during the coming years.
than 0.1% of the total number of pores; the small pores
(radii of 40 to 50 A˚) that are involved in the transport
VIRTUAL NON-GLUCOSE OSMOTIC AGENTS of low molecular weight molecules such as glucose, urea,
IN PERITONEAL DIALYSIS creatinine and 2-microglobulin, corresponding to 50 to
A peritoneal dialysis solution containing glucose poly- 60% of the total number of pores; and finally the ultra-
mers as osmotic agent differs from the glucose-based so- small, “transcellular” aquaporin pores (radii smaller than
lution, since it induces transcapillary ultrafiltration with- 3 A˚) that are involved only in water, but not solute
out being hypertonic. The icodextrin-based solution is transport.
currently the only safe and efficient non-glucose large
Icodextrin and peritoneal fluid transportmolecular weight osmotic agent for the long dwell and it
is now available in several countries for clinical use (Extra- Macromolecules such as glucose polymers can induce
neal; Baxter Healthcare, McGaw Park, IL, USA). The transcapillary ultrafiltration even under isotonic condi-
icodextrin-based solution is a polymer of glucose pro- tions. The process of colloid osmosis is based on the prin-
duced by the hydrolysis of cornstarch and it contains a ciple that water is transported from the capillaries in the
spectrum of polymer molecules with an average molecu- direction of relative excess of impermeable large solutes,
lar weight of 16.2 kD [29]. The polymers consist of glu- rather than down an osmotic gradient (as in the case
cose units linked predominantly by-1-4 glucosidic bonds, of glucose-based solutions). This process implies that
with a small proportion of branches linked by -1-6 glu- icodextrin removes fluid from the body by inducing water
cosidic bonds. After absorption, the polymers are de- transport through small pores. Since the icodextrin solu-
graded to disaccharides, maltose, and eventually glucose tion is not hypertonic in relation to the plasma, no trans-
port through the ultra-small pores is induced. Based on[30]. Icodextrin is iso-osmolar (285 mOsm/kg) to the
the reflection coefficients of urea, creatinine, urate andplasma, and its pH is 5.2 to 5.6. From a metabolic point
glucose, the average reflection coefficient for icodextrinof view, icodextrin can be considered as a virtual non-
was estimated as 0.76, implying that the maximal pressureglucose osmotic agent because of the slow release of glu-
gradient across the peritoneal membrane was 37 mm Hg,cose molecules from icodextrin (a description of the met-
in contrast to the 88 mm Hg exerted by 3.86% glucoseabolic effects of icodextrin can be found elsewhere in
solution [35]. Because of its low absorption from thethis Supplement issue).
dialysate, icodextrin maintains this gradient for severalThe ultrafiltration yielded by a 7.5% icodextrin-based
hours, and after a seven-hour dwell, a 36 mm Hg pressuredialysis solution is higher than the ultrafiltration gener-
difference is still present, whereas this pressure differ-ated by 1.36% glucose (1.5% dextrose) solutions during
ence approaches zero when glucose-based solutions area six-hour dwell, despite its lower osmolality (285 vs.
used. As a result, sustained ultrafiltration is obtained347 mOsm/kg). This demonstrates the colloid osmotic
with icodextrin even during very long dwells. Further-(instead of crystalloid osmotic) mechanism of action of
more, it is possible that icodextrin results in decreasedicodextrin. Moreover, when used for the 8 to 12 hour
fluid reabsorption from the dialysate [36], further con-long-dwell in CAPD and APD patients, icodextrin 7.5%
tributing to improved net ultrafiltration.provides equivalent or higher ultrafiltration than that
provided by 3.86% (486 mOsm/kg) glucose (4.25% dex-
Icodextrin and peritoneal sodium transporttrose) solution [29, 31, 32].
During peritoneal dialysis, sodium is transported by
diffusion (dependent upon the gradient between plasma
EFFECT OF ICODEXTRIN ON and dialysate), by convection due to ultrafiltration, and
PERITONEAL TRANSPORT by convection due to peritoneal fluid absorption (lym-
There are several barriers to solutes and water trans- phatic and interstitial absorption). The sodium transport
is dependent upon the concentration of glucose solutionport from peritoneal capillaries into the peritoneal cav-
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Fig. 1. Proposed pathways for the peritoneal transport of fluid and solutes based on the three pore model and experimental and clinical data.
The prevailing transport routes when glucose-based solution (including the glucose absorption that occurs in long dwells) is used (left) and when
icodextrin-based solutions is used (right).
used and transport characteristics of the membrane, and portant determinant of small solute transport (the peri-
toneal membrane surface area available for diffusivenet sodium removal is highly correlated to the net ultra-
filtration [37]. A detailed evaluation of sodium transport transport) was not influenced by the tonicity or type of so-
lution evaluated. Thus, the increased dialysate volume(taking into account peritoneal absorption) with ico-
dextrin solutions has not yet been performed, but one results in increased removal of small solutes. This has
been documented clinically in studies of icodextrin, incan assume that due to characteristics of the icodextrin
solutions, beneficial effects on sodium removal during which the higher ultrafiltration response with icodextrin
in comparison to 2.5% dextrose solutions was also mani-the long-dwell can be extrapolated due to the prolonged
ultrafiltration profile in combination with less sieving of fested in higher solute clearance [38].
sodium. Indeed, Plum et al recently showed that the total
Icodextrin and peritoneal transport of proteinsdialysate sodium removal increases when icodextrin is
used as an osmotic agent [38]. Moreover, because there In single dwell studies comparing icodextrin to glucose
is an absence of sodium sieving during the icodextrin solutions, 2-microglobulin removal was significantly
dwell, the amount of sodium per volume of ultrafiltrate is higher with the use of icodextrin [32, 35]. These findings
expected to be higher than sodium removed with osmotic of higher clearance of small proteins with the use of ico-
agents associated with high sodium sieving (that is, glu- dextrin support the hypothesis that icodextrin acts through
cose solutions). the small pores, and also that icodextrin increases the
“solvent drag.” This phenomenon most likely is caused
Icodextrin and peritoneal small solutes transport by increased convective transport of solutes including
peptides and small proteins through the small pores.Pannekeet et al have shown similar mass transfer area
coefficients of urea, creatinine and urate, comparing 3.86% The radius of 2-microglobulin (16 A˚) allows its passage
through the small pore system. In contrast, when clear-glucose (4.25% dextrose) and 7.5% icodextrin solutions
in a four-hour dwell [39]. This implies that the most im- ances of albumin (36 A˚) and 2-macroglobulin were ana-
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Fig. 2. Possible local (peritoneal membrane) and systemic effects of icodextrin solutions. Question marks denote possible but not yet documented
effects, which should be subject of future studies.
lyzed, no differences between icodextrin and hypertonic compared to hyperosmolar glucose solutions [42, 43]. Sev-
glucose solutions were found [39]. The same findings eral ex vivo studies have demonstrated improvements in
were present when Krediet et al analyzed clinically stable both peritoneal and mesothelial cell function in patients
patients before and four weeks after the initiation of ico- using icodextrin-based dialysis solution, while using con-
dextrin use for the overnight dwell. A 28% increase in ventional solutions for all other exchanges [44, 45]. Ico-
the 2-microglobulin transport was observed, due to an dextrin has been demonstrated to exert no long-term
increase in convective transport [40]. This mechanism of toxicity, and some studies suggested that it is more bio-
action on small protein removal can result in further compatible to the peritoneum than glucose, particularly
potential benefits of icodextrin solutions. In this line of due to its isoosmolarity [42]. In addition, the concentra-
rationale, Opatrna et al showed higher leptin removal tion of glucose degradation products of the icodextrin-
with the use of icodextrin, compared to glucose solutions based dialysis solution is very low compared to that of
(abstract; Perit Dial Int 22:116, 2002). Acute studies on glucose-containing solutions, yielding a significant reduc-
appetite in an experimental rat model indicate that ico- tion in in vitro cell cytotoxicity, glycation of proteins,
dextrin-based dialysis solutions may result in less inhibi- Amadori adduct formation, and advanced glycation end
tion of appetite than glucose based solutions; this effect product (AGE) formation [46]. In fact, Ho-dac-Pannekeet
is most likely due to the avoidance of rapid glucose et al presented information indicating that treatment
absorption [41]. With the potential adverse effects of with icodextrin-based solutions results in decreased gly-
leptin on appetite, and atherosclerosis in mind, further
cosylated proteins in the peritoneal membrane [47]. Thestudies are needed to analyze the consequences of higher
icodextrin-based solutions therefore potentially mayremoval of leptin in PD patients treated with icodextrin.
contribute to preserve the structural and functional prop-The same concept could be applied to the effects of
erties of the peritoneal membrane (Fig. 2).icodextrin removal of other small proteins of the same
molecular weight. This is yet another area for future
studies. The prospect of improving the clearance of mid- SYSTEMIC EFFECTS OF
dle molecules is very promising. ICODEXTRIN SOLUTIONS
In addition to these local effects, the icodextrin solu-
LOCAL (INTRAPERITONEAL) EFFECTS OF tion also may have various positive systemic effects
ICODEXTRIN SOLUTIONS (Fig. 2). The most well-documented systemic effects are
related to improved fluid removal in patients with in-The isoosmolar icodextrin solution may be potentially
less damaging to the peritoneum and to peritoneal defense creased peritoneal surface area as demonstrated in com-
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Table 2. Advantages of icodextrin-based solutions over 4.25% FUTURE CLINICAL USE OF
dextrose solutions in peritoneal dialysis
ICODEXTRIN SOLUTIONS
Functional advantages There is now an extensive clinical experience with the
• Long-lasting ultrafiltration
icodextrin-based solution, and its efficacy and safety are• Superior ultrafiltration in high and high average transporters
• Higher clearance of middle molecules (2-microglobulin) well documented. Long-term clinical experience now ex-
• Greater sodium removal per ultrafiltrate volume tends over many years in an increasing number of pa-
Metabolic advantages
tients [31, 38, 50, 52, 58], and it has been demonstrated• Absence of hyperglycemia and hyperinsulinemia
• Lower caloric load that this solution may extend CAPD technique survival
• No rapid abdominal distension and less acute discomfort in patients with UF failure [51]. Therefore, it is likely
• Lower glucose degradation products
that this solution will become the standard solution for• No hyperosmolar damage to peritoneal membrane
• No peritoneal glucose exposure the long dwell in PD. Further developments, such as the
combination of a lower concentration of icodextrin with
glucose [abstract; Jenkins et al, Perit Dial Int 22(Suppl
1):S118, 2002] and perhaps other osmotic agents such as
puter simulations [48] and in clinical studies [32]. Icodex- amino acids [2] and glycerol [59] possibly could extend
trin has been used successfully during peritonitis [49, 50], its future use to also encompass shorter exchanges.
and can prevent the temporary decline of ultrafiltration
due to the increased absorption of glucose induced by
SUMMARYthe inflammation and vasodilation in the peritoneal
In summary, the use of icodextrin as an osmotic agentmembrane, when using glucose based solutions [39, 51].
increases ultrafiltration during the long dwell in PD pa-Indeed, the ultrafiltration profile was considerably better
tients, particularly during peritonitis and in high trans-in patients with signs of intraperitoneal inflammation, as
porters. Thus, the effect of icodextrin is most powerfulestimated by the intraperitoneal levels of interleukin-6
precisely in those patients who need it most, namely the[abstract; Pecoits-Filho et al, Perit Dial Int 22(Suppl
high transporters. A major advantage is that icodextrin1):S13, 2002]. Furthermore, icodextrin may be of particu-
provides increased ultrafiltration and clearances duringlar value in high transporters [32, 52]. Improved fluid
long dwells, while avoiding problems with excessive glu-removal may have various positive effects. For example,
cose absorption. Various unwanted systemic and localin a crossover study, Woodrow et al reported reduction
effects of the standard glucose-based dialysis solutionsof the anti-hypertensive medication in 6 out of 14 APD
can be avoided with the use of icodextrin (Table 2), andpatients using icodextrin. Furthermore, blood pressure
this may potentially improve both technique survival andwas significantly reduced, and this effect correlated with
patient survival especially in PD patients with inade-changes in body weight and body water compartments
quate UF. Therefore, it is likely that the icodextrin-basedestimated by multifrequency bioelectrical impedance.
solution will be the standard solution for the long dwellThese authors concluded that the use of icodextrin for
in the majority of PD patients in the future.the daytime dwell in APD results in improved fluid and
blood pressure control [53]. Additionally, in terms of the Reprint requests to Bengt Lindholm, M.D., Ph.D., Divisions of Bax-
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